PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46
- Conditions
- Healthy
- Interventions
- Biological: TA-46Other: Placebo
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT04410809
- Locations
- 🇳🇱
PRA, Groningen, Netherlands
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 974
- Registration Number
- NCT04408794
- Locations
- 🇺🇸
Ki Health Partners, LLC dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸Pharmacology Research Institute, Los Alamitos, California, United States
PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT04403776
- Locations
- 🇨🇳
Shuguang Hospital Affiliated to Shanghai University of TCM/Phase I Unit, Shanghai, China
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
- Conditions
- Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT04399538
- Locations
- 🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸Excel Medical Clinical Trials, Boca Raton, Florida, United States
🇺🇸Optimus U Corporation, Miami, Florida, United States
Actigraphy Improvement With Voxelotor (ActIVe) Study
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT04400487
- Locations
- 🇺🇸
The Children's Hospital at Montefiore, Bronx, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 486
- Registration Number
- NCT04398732
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients
- Conditions
- Hemophilia A
- Interventions
- Biological: Moroctocog-alfa (AF-CC)
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT04396639
- Locations
- 🇮🇳
Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India
🇮🇳Christian Medical College and Hospital, Ludhiana, Punjab, India
🇮🇳Nirmal Hospital, Surat, Gujarat, India
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
- Conditions
- Breast Cancer
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 975
- Registration Number
- NCT04396626
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 242
- Registration Number
- NCT04394247
- Locations
- 🇺🇸
Syapse, San Francisco, California, United States
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 164
- Registration Number
- NCT04390776
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States